ReviewThe Lancet. Global health2024
Paving the way for affordable and equitable liposomal amphotericin B access worldwide.
Review in The Lancet. Global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- Antifungal-induced DNA dynamics and chitin remodelling across Cryptococcus spp. and the novel broad-spectrum anti-cryptococcal candidate CPTH2.Scientific reports · 2026Article
- Targeting the polyene chain represents an adjuvant strategy for optimizing polyene antifungals.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Review
- Leishmania donovani's protein tyrosine phosphatases interact with DUF21 and respond to environmental magnesium.The FEBS journal · 2026Article
- Use of DOOR and Win-Ratio Analysis in a Secondary Evaluation of a Histoplasmosis Clinical Trial.Open forum infectious diseases · 2026Article
- An analysis of national guidelines for the prevention, diagnosis and treatment of cryptococcal meningitis in sub-Saharan African countries: gaps and opportunities.BMJ global health · 2026Article
- Ensuring effective transitions in care for hospitalized people living with HIV.Frontiers in public health · 2026Review
- Amphotericin B Colloidal Dispersion Is Effective and Safe for the Treatment of Invasive Aspergillosis in Chinese Patients with Hematologic Disease: A Multicenter, Prospective, Observational, Real-World Study.Drug design, development and therapy · 2026Observational
- Dosing and safety of amphotericin B deoxycholate in paediatric American cutaneous leishmaniasis in Peru: a case series.BMC infectious diseases · 2025Article
- Antifungal treatment strategies and their impact on resistance development in clinical settings.The Journal of antimicrobial chemotherapy · 2025Review
- Assessment of Clinical Guideline Use in the Prevention, Diagnosis, and Treatment of Cryptococcal Meningitis Among Health Care Providers in Ethiopia.Open forum infectious diseases · 2025Article
- Management of mould pneumonia in resource-limited settings in Asia: A Delphi-based consensus statement by the Asia Fungal Working Group.Medical mycology · 2025Article
- Article
- Antifungal Drugs for the Treatment of Invasive Fungal Infections-A Limited Therapeutic Toolbox Facing Growing Resistances.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The conundrum of antifungal resistance: Emergence of Nakaseomyces glabratus (Candida glabrata) in Europe with global implications.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Dicentrine Purified from the Leaves ofMicroorganisms · 2025Article
- Cutaneous leishmaniasis: epidemiology, treatment access and translational challenges of topical therapies.Frontiers in microbiology · 2025Review
- Efficacy and Safety of Amphotericin B Colloidal Dispersion via Nebulized Inhalation Combined with Intravenous Therapy for Invasive Pulmonary Fungal Disease: A Single-Center, Retrospective Cohort Study.Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Amphotericin B has long been crucial for treating many serious infectious diseases, such as invasive fungal infections and visceral leishmaniasis, particularly for patients who are immunocompromised, including those with advanced HIV infection. The conventional amphotericin B deoxycholate formulation has largely been replaced in high-income countries with liposomal amphotericin B (LAmB), which has many advantages, including lower rates of adverse events, such as nephrotoxicity and anaemia. Despite an evident need for LAmB in low-income and middle-income countries, where mortality from invasive fungal infections is still substantial, many low-income and middle-income countries still often use the amphotericin B deoxycholate formulation because of a small number of generic formulations and the high price of the originator LAmB. The pricing of LAmB is also highly variable between countries. Overcoming supply barriers through the availability of additional quality-assured, generic formulations of LAmB at accessible prices would substantially facilitate equitable access and have a substantial effect on mortality attributable to deadly fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.